A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19 (Bronx)
AstraZeneca Vaccine: Study of AZD1222 for the Prevention of COVID-19 in Adults (Bronx)
Sponsor: AstraZeneca
Enrolling: Male and Female Patients
Study Length: 24 Months
Clinic Visits: 7
IRB Number: AAAT2402
U.S. Govt. ID: NCT04516746
Contact: Logan Posey: 347-590-7280 / lp2907@cumc.columbia.edu
Additional Study Information: The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19. The COVID-19 pandemic has caused major disruption to healthcare systems with significant socioeconomic impacts. Currently, there are no specific treatments available against COVID-19 and accelerated vaccine development is urgently needed. A safe and effective vaccine for COVID-19 prevention would have significant public health impact.
This study is closed
Jessica Justman, MD
Do You Qualify?
Are you 18 years old or older? Yes No
Have you ever tested positive for Sars-Co-V-2 (Covid-19)? Yes No
Are you currently pregnant? If N/A select No. Yes No
Are you preventing pregnancy (i.e. birth control)? If N/A select Yes. Yes No
Are you willing to travel to the South Bronx for participation in this study? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Logan Posey